OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024
May 08, 2024 at 04:05 pm EDT
Share
OraSure Technologies, Inc. provided revenue guidance for the second quarter of 2024. The Company is guiding to second quarter of 2024 revenue of $50 million to $55 million, which includes core revenue of $33 million to $36 million and InteliSwab revenue of $17 million to $19 million. Second Quarter 2024 guidance includes approximately $650,000 of revenue from the Diversigen business that plan to exit.
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
ORASURE TECHNOLOGIES, INC. 
